Simplicity Solutions LLC Purchases Shares of 32,628 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Simplicity Solutions LLC purchased a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the 4th quarter, HoldingsChannel reports. The fund purchased 32,628 shares of the company’s stock, valued at approximately $81,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VTYX. BlackRock Inc. increased its stake in Ventyx Biosciences by 57.5% in the second quarter. BlackRock Inc. now owns 3,226,572 shares of the company’s stock valued at $105,832,000 after purchasing an additional 1,177,971 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Ventyx Biosciences by 163.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,805,574 shares of the company’s stock valued at $59,205,000 after purchasing an additional 1,120,232 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Ventyx Biosciences by 962.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 987,970 shares of the company’s stock valued at $34,312,000 after purchasing an additional 895,000 shares in the last quarter. FMR LLC increased its stake in Ventyx Biosciences by 92.9% in the second quarter. FMR LLC now owns 1,575,942 shares of the company’s stock valued at $19,274,000 after purchasing an additional 758,903 shares in the last quarter. Finally, Holocene Advisors LP increased its stake in Ventyx Biosciences by 48.3% in the second quarter. Holocene Advisors LP now owns 1,537,084 shares of the company’s stock valued at $50,416,000 after purchasing an additional 500,571 shares in the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Stock Up 2.8 %

Shares of VTYX stock opened at $4.47 on Monday. Ventyx Biosciences, Inc. has a 52-week low of $1.87 and a 52-week high of $40.58. The company has a 50-day simple moving average of $5.92 and a two-hundred day simple moving average of $6.17.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.08. During the same quarter in the prior year, the company earned ($0.62) earnings per share. Equities research analysts predict that Ventyx Biosciences, Inc. will post -2.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

VTYX has been the subject of several recent research reports. Canaccord Genuity Group decreased their target price on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Lifesci Capital raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Oppenheimer raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Tuesday, March 12th. Finally, Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $7.00 to $16.00 in a research report on Tuesday, March 12th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Ventyx Biosciences has an average rating of “Moderate Buy” and a consensus price target of $21.75.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.